Weight-loss diets, adiponectin, and changes in cardiometabolic risk in the 2-year pounds lost trial

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 6, 2016, Pages 2415-2422

  Ma, Wenjie ^a   Huang, Tao ^b   Zheng, Yan ^a   Wang, Molin ^a   Bray, George A ^c   Sacks, Frank M ^a   Qi, Lu ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b TULANE UNIVERSITY   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DIET THERAPY; FEMALE; FOOD COMPOSITION; HUMAN; LONG TERM CARE; MACRONUTRIENT; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; BLOOD; BODY MASS; CARDIOVASCULAR DISEASES; COMPLICATION; LOW CALORY DIET; METABOLIC DISEASES; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADIPONECTIN; ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIET, REDUCING; FEMALE; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK FACTORS; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 84973571921     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-1207     Document Type: Article

References (44)

1. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925-1932.
2. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2960-2984.
3. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859-873.
4. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a lowcarbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008; 359:229-241.
5. Pi-Sunyer FX. The relation of adipose tissue to cardiometabolic risk. Clin Cornerstone. 2006;8(suppl 4):S14-S23.
6. Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: Exploring the connection. Arterioscler Thromb Vasc Biol. 2007;27:996-1003.
7. Varady KA, Hellerstein MK. Do calorie restriction or alternate-day fasting regimens modulate adipose tissue physiology in a way that reduces chronic disease risk? Nutr Rev. 2008;66:333-342.
8. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6: 772-783.
9. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond). 2008;114:361-374.
10. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: An update. Br J Pharmacol. 2012;165:574-590.
11. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-1792.
12. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947-953.
13. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-1295.
14. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med. 2005;11:1096-1103.
15. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100.
16. Weiss EP, Racette SB, Villareal DT, et al. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: A randomized controlled trial.Am J Clin Nutr. 2006;84:1033-1042.
17. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA. 2003;289:1799-1804.
18. Xydakis AM, Case CC, Jones PH, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: The impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004;89:2697-2703.
19. Claessens M, van Baak MA, Monsheimer S, Saris WH. The effect of a low-fat, high-protein or high-carbohydrate ad libitum diet on weight loss maintenance and metabolic risk factors. Int J Obes (Lond). 2009;33:296-304.
20. Simons-Morton DG, Obarzanek E, Cutler JA. Obesity research-limitations of methods, measurements, and medications. JAMA. 2006;295:826-828.
21. Heidemann C, Sun Q, van Dam RM, et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med. 2008;149:307-316.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
23. Chan DC, Watts GF, Ng TW, Yamashita S, Barrett PH. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Eur J Clin Invest. 2008;38:743-751.
24. Heinonen MV, Laaksonen DE, Karhu T, et al. Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2009;19: 626-633.
25. Christiansen T, Paulsen SK, Bruun JM, Pedersen SB, Richelsen B. Exercise training versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in obese subjects: A 12-week randomized intervention study.Am J Physiol Endocrinol Metab. 2010; 298:E824-E831.
26. Belza A, Toubro S, Stender S, Astrup A. Effect of diet-induced energy deficit and body fat reduction on high-sensitive CRP and other inflammatory markers in obese subjects. Int J Obes (Lond). 2009;33: 456-464.
27. Larrouy D, Barbe P, Valle C, et al. Gene expression profiling of human skeletal muscle in response to stabilized weight loss. Am J Clin Nutr. 2008;88:125-132.
28. Klempel MC, Varady KA. Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans. Nutr Rev. 2011;69:145-154.
29. Salas-Salvado J, Bullo M, Garcia-Lorda P, et al. Subcutaneous adipose tissue cytokine production is not responsible for the restoration of systemic inflammation markers during weight loss. Int J Obes (Lond). 2006;30:1714-1720.
30. Tsubakio-Yamamoto K, Sugimoto T, et al. Serum adiponectin level is correlated with the size of HDL and LDL particles determined by high performance liquid chromatography. Metabolism. 2012;61: 1763-1770.
31. Rothenbacher D, Brenner H, März W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J. 2005;26:1640-1646.
32. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730-1737.
33. Belalcazar LM, Lang W, Haffner SM, et al. Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: The Look AHEAD Study. J Lipid Res. 2012;53:2726-2733.
34. Matsuura F, Oku H, Koseki M, et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun. 2007;358:1091-1095.
35. Oku H, Matsuura F, Koseki M, et al. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett. 2007;581:5029-5033.
36. Tsubakio-Yamamoto K, Matsuura F, et al. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun. 2008;375:390-394.
37. Vergès B, Petit JM, Duvillard L, et al. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol. 2006;26:1364-1369.
38. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
39. Guenther M, James R, Marks J, Zhao S, Szabo A, Kidambi S. Adiposity distribution influences circulating adiponectin levels. Transl Res. 2014;164:270-277.
40. Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab. 2003;88:4823-4831.
41. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA. 2001;98:2005-2010.
42. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med. 2004;10:524-529.
43. Belalcazar LM, Lang W, Haffner SM, et al. Improving adiponectin levels in individuals with diabetes and obesity: insights from look AHEAD. Diabetes Care. 2015;38:1544-1550.
44. Smith JD, Hou T, Hu FB, et al. A comparison of different methods for evaluating diet, physical activity, and long-term weight gain in 3 prospective cohort studies. J Nutr. 2015;145:2527-2534.